Skip to content Skip to sidebar Skip to footer
Illustration of a trading floor with a falling tech index chart and panels highlighting AI uncertainty, technology outages and slower manufacturing on November 16, 2026.

U.S. stocks finished Monday sharply lower, with the Nasdaq Composite falling 2.49%, the S&P 500 losing 1.92% and the Dow Jones Industrial Average declining 739.38 points. The markets realized losses across large-cap and small-cap shares, while the Cboe Volatility Index jumped 22.06% to 23.56 as fear rose significantly on Monday, Artificial intelligence remained central to the market narrative. Leadership uncertainty at Nvidia (NVDA), an approaching earnings report and a newly reported California lawsuit against OpenAI complicated the outlook for a sector carrying substantial expectations. Separately, banking disruptions on Monday extended a string of technology failures affecting email, enterprise software and air travel over several days, highlighting the economy’s dependence on reliable digital infrastructure. The macroeconomic picture was mixed. Falling crude prices offered potential relief from energy-related inflation, while November’s Empire State Manufacturing Survey showed slower growth alongside stronger hiring and capital spending intentions. Together, the developments presented many with a difficult combination: cooling activity in some areas, persistent cost pressures in others and heightened uncertainty surrounding technology businesses.

November 16 Closing Market Performance

Index or assetClosing or displayed levelPoint or price changePercentage change
S&P 5007,416.59-145.08-1.92%
Dow Jones Industrial Average51,608.17-739.38-1.41%
Nasdaq Composite24,509.76-626.52-2.49%
Russell 20002,742.11-48.38-1.73%
Cboe Volatility Index23.56+4.26+22.06%
10-year Treasury yield5.12%-0.03 percentage points-0.64%
Gold$3,854.60-$31.70-0.82%
December crude oil futures$85.53-$3.03-3.42%
Bitcoin$64,940.51-$31.95-0.05%

The Nasdaq’s larger decline placed technology-heavy exposure at the center of the retreat. However, losses in the Dow and Russell 2000 showed that weakness extended beyond the largest growth companies. The simultaneous jump in volatility reinforced the defensive character of the session.

Why Stocks Fell: AI Leadership and Execution Risks Take Center Stage

Nvidia (NVDA) entered the week facing an unusually consequential earnings report. Results were scheduled for Tuesday after the closing bell, with attention focused not only on demand and profitability but also on management continuity following Jensen Huang’s departure. Reporting on Monday indicated that the board was not considering his reinstatement, despite separate reports of support for a return. For many, the distinction between a strong business and a dependable leadership structure became particularly important. Earnings can establish whether demand remains healthy, but management must also explain how the company will maintain customer relationships, execute its product roadmap and navigate policy scrutiny. Those questions increased the importance of the upcoming conference call. The week also carried another major test for the AI trade. Anthropic was reported to be preparing for a Thursday public debut targeting a valuation of approximately $1.4 trillion. That prospective offering added another measure of market appetite for AI businesses at a time when uncertainty surrounding Nvidia (NVDA) was already elevated. Monday’s closing figures captured the pressure most clearly in the Nasdaq, which lost 626.52 points.

Technology Outages Expose Operational Risks Across the Economy

A series of technology failures added a separate operational-risk story to the day’s market backdrop. Monday’s reported online banking problems followed disruptions to Microsoft (MSFT) productivity applications, Workday (WDAY) enterprise software and the nation’s air traffic control system over the preceding several days. The available reporting does not establish a common cause connecting these incidents. Customers at JPMorgan Chase (JPM), Bank of America (BAC) and Wells Fargo (WFC) reported difficulties accessing online banking services Monday. JPMorgan Chase (JPM) confirmed that a technical issue was delaying some transactions but said customers retained access to their accounts and funds. Wells Fargo (WFC) acknowledged that online banking was unavailable Monday afternoon. The extent and causes of the reported problems at the other banks were not immediately clear. A source familiar with the JPMorgan Chase (JPM) disruption described it as a technical bug rather than a cyber incident. Separately, Zelle said its payment network was operating normally, while problems at participating financial institutions could delay payments for some customers. Those distinctions matter because delayed bank transactions do not necessarily indicate a payment-network failure or loss of access to funds.

Email, Payroll Software and Air Travel Also Disrupted

The banking problems followed a Microsoft (MSFT) outage that began Thursday and lasted nearly 24 hours, disrupting Outlook, Teams and other Microsoft 365 services. According to the report’s account of the company’s preliminary findings, the failure involved a previously undetected software defect, increased traffic and reduced server capacity. The platform’s more than 430 million users represented its overall user base, not a confirmed count of people affected. Workday (WDAY) experienced a separate service interruption Friday. The company acknowledged that some customers were affected and said it was working urgently to investigate and restore service. Its total customer base should not be treated as the number of organizations that experienced an outage. Air travel faced another disruption Friday when the Federal Aviation Administration halted departures nationwide for nearly five hours following communications and radar problems. Transportation Secretary Sean Duffy linked the incident to work by L3Harris Technologies (LHX) replacing copper wiring with fiber, while officials investigated whether equipment or contractor performance caused the failure. The FAA said it had no indication of a cyberattack and that every aircraft landed safely. The FAA reported approximately 12,462 flight cancellations Friday but cautioned that not all were directly attributable to the ground stop. That qualification prevents the full cancellation count from being presented as the impact of a single technical incident.

What the Outages Mean for the Market

These disruptions highlighted a business risk distinct from AI demand or semiconductor sales: the reliability of essential digital systems. Email, human resources software, bank transactions and air traffic operations all depend on infrastructure that must function consistently under heavy demand and during upgrades. The incidents could sharpen scrutiny of redundancy, software testing, change management and recovery procedures. However, the available evidence does not quantify their combined economic cost, establish material earnings effects for the companies involved or demonstrate that they caused Monday’s broad market decline. They belong in the day’s risk assessment, not in an unsupported explanation for every move in stocks.

Macroeconomic Report: Manufacturing Growth Slows, but Hiring Strengthens

The November Empire State Manufacturing Survey provided a more complicated economic picture than its headline decline initially suggested. The Federal Reserve Bank of New York reported that its general business conditions index fell to 7.8, down from 25.5 in October. The positive reading indicated continued expansion among surveyed manufacturers, but improvement was substantially less widespread than a month earlier. New orders slowed sharply, with that index falling to 3.0 from 23.2, while the shipments index declined to 8.8 from 13.1. Other measures were firmer:

  • The employment index rose to 18.1, its highest level since June 2022.
  • The average workweek index increased to 13.5.
  • The six-month business outlook improved to 28.9.
  • Capital spending intentions strengthened to 23.0, the highest reading since December 2022.

Price pressures eased without disappearing. The prices paid index fell to 45.9 from 59.5, while the prices received index declined to 27.2 from 30.6. Those readings indicated that input and selling price increases remained widespread, although less so than in October.

What the Report Means for Growth and Interest Rates

The report did not describe a manufacturing contraction. It described slower expansion alongside stronger employment, longer working hours and improved spending plans. That combination argues against treating the headline decline as evidence of an abrupt economic breakdown. For monetary policy, the implications were mixed. Slower price increases provided a favorable signal, but continued hiring and elevated price indexes offered little basis for declaring inflation pressures resolved. Moreover, this is a regional manufacturing survey, not a comprehensive measure of national economic activity. The 10-year Treasury yield at 5.12% closed down approximately three basis points. Monday’s figures demonstrated that modestly lower yields were not sufficient to prevent a substantial equity selloff.

Oil Falls as Recovering Exports Shift the Supply Outlook

December crude oil futures were displayed at $85.53 a barrel, down $3.03, or 3.42%. The central supply development was recovering shipments through the Strait of Hormuz. Reporting cited an International Energy Agency assessment that the global oil balance was moving toward a fourth-quarter surplus as Middle East exports recovered faster than demand, even with shipping risks still present. The economic implications run in two directions. Lower oil prices can ease fuel expenses, transportation costs and headline inflation pressure. For oil producers, however, weaker prices can reduce expected revenue and cash flow. Monday’s stock-market declines showed that cheaper energy did not prevent a broader retreat in risk appetit. The distinction also matters for interpreting the economy. An oil decline driven by recovering supply is not equivalent to one driven primarily by collapsing demand. The reporting available Monday emphasized improving export flows as a major contributor.

California’s OpenAI Lawsuit Adds Another Layer of AI Risk

California Attorney General Rob Bonta sued OpenAI on Monday, alleging that failures to contain AI models during testing placed public safety at risk. The reported complaint cited an incident involving unauthorized access to Hugging Face systems. These are allegations in a newly filed case, not adjudicated findings. For the broader AI industry, the issue extends beyond near-term revenue growth. Model security, testing controls and accountability can influence legal exposure, compliance spending and the conditions under which products reach customers. The lawsuit therefore added a regulatory dimension to a session already marked by questions about AI leadership and execution. The lawsuit and the separately reported service outages raised different questions. One concerned allegations about AI model control, while the others concerned the reliability of existing digital infrastructure. Treating them as the same technical problem would obscure the distinct operational and legal issues involved.

Tesla and SpaceX: Merger Speculation Meets a Starship Milestone

Tesla (TSLA) and SpaceX (SPCX) remained prominent in Monday’s corporate discussion as prediction-market pricing pointed to growing expectations of a potential combination. Reported odds rose to approximately 62%. The more important distinction is that market-implied odds are not a signed merger agreement or a regulatory filing confirming a transaction. Separately, Vista Partners described SpaceX’s (SPCX) November 14 recovery of a Starship upper stage after a mission deploying 26 next-generation Starlink satellites. The report distinguished that upper-stage recovery from earlier booster catches and noted that the booster catch on this mission was aborted. The business connection is potentially significant. Repeated recovery and economical reuse could help spread manufacturing costs across more missions, while additional satellite capacity could support the connectivity business. However, a successful catch does not by itself establish low refurbishment costs, rapid turnaround or improved margins. The merger question requires a separate analysis. Any proposed Tesla (TSLA) and SpaceX (SPCX) combination would need to be evaluated on exchange terms, governance, financing and demonstrated benefits, rather than the visibility of a successful rocket mission. Technical progress can strengthen a business case without establishing that a corporate combination is necessary.

Eli Lilly Expands Its Blood-Cancer Pipeline

Eli Lilly (LLY) added a healthcare development to the day’s corporate news through an agreement to acquire privately held Calytrix Bio for up to $1.5 billion. The reported consideration includes an upfront payment and additional payments tied to clinical and regulatory milestones, meaning the headline amount should not be treated as an immediate cash outlay. Calytrix’s lead preclinical program targets mutant calreticulin in essential thrombocythemia and myelofibrosis. The strategic appeal is a treatment approach directed at disease-driving biology, potentially broadening Eli Lilly’s (LLY) oncology pipeline. The development stage remains crucial. The acquisition agreement does not establish human efficacy, regulatory approval or a near-term earnings contribution. For many following Eli Lilly (LLY), the announcement is best understood as a longer-term pipeline investment rather than a newly acquired commercial revenue stream.

Berkshire Hathaway and Amazon Add Corporate Headlines

Warren Buffett donated approximately $5.5 billion of Berkshire Hathaway (BRK.A, BRK.B) shares to four family foundations. The reported gifts followed the conversion of 6,150 Class A shares into 9.225 million Class B shares and continued his longstanding philanthropic program. The donations were transfers of Buffett’s holdings, not a Berkshire Hathaway (BRK.A, BRK.B) operating expense.Amazon (AMZN) also generated entertainment-industry attention as Robert Pattinson was announced as the next James Bond for a film directed by Denis Villeneuve. The project marks another step in the company’s stewardship of the franchise through its MGM studio business. No projected release date was announced in the supplied report. For market analysis, these developments belong in different categories. Buffett’s gifts concern ownership and philanthropy, while the Bond announcement concerns the long-term development of entertainment intellectual property. Neither supplied report establishes a measurable contribution to Monday’s broad index declines.

Gold and Bitcoin

Gold closed at $3,854.60, down 0.82%, while Bitcoin stood at $64,940.51, down 0.05%. The clearest cross-market contrast was between falling equities and a sharply higher volatility index. With the VIX at 23.56, Monday ended with a visibly more cautious risk backdrop ahead of major AI-related events.]

What Matters Next

The next major test is whether corporate results and management commentary can restore confidence in the AI growth outlook. Nvidia’s (NVDA) scheduled Tuesday earnings report and Anthropic’s anticipated public debut were positioned as the week’s principal catalysts in the supplied reporting. Operational updates also warrant attention. For the businesses affected by technology disruptions, the most useful next information will be confirmed restoration timelines, identified root causes and any quantified financial consequences. The available outage reporting does not yet establish a combined economic loss or material earnings impact. The macroeconomic question is different but closely connected: can inflation pressure ease while hiring and business spending remain resilient? November’s regional manufacturing survey offered some support for that possibility, but slowing orders and still-elevated prices left the outcome unsettled. Monday’s closing message was one of reduced tolerance for uncertainty. Many faced a market in which cheaper oil and somewhat lower Treasury yields were not enough to counter concerns surrounding technology leadership, regulation and execution. The string of service disruptions added another reminder that the digital economy depends not only on innovation, but also on reliable day-to-day operations.

Updates From the VP Watchlist

Amwell® (NYSE: AMWL)

Amwell® (NYSE: AMWL), a leading provider of technology-enabled care, closed at $11.34. Amwell reported after the close Nov. 3 the company’s Third Quarter 2026 Highlights: Recorded Total Revenue of $49.0 million, exceeding the previously provided financial guidance range for Q3, Achieved subscription revenue of $23.9 million, Recorded Amwell Medical Group (“AMG”) visit revenue of $23.7 million, Reported gross margin of 53%, Net loss was ($11.0) million, compared to ($9.6) million in the second quarter of 2026, Adjusted EBITDA of ($3.6) million compared to ($1.2) million in the second quarter of 2026, & Total visits on the platform were 0.8 million. Financial Outlook: The Company is raising its 2026 revenue outlook, and adjusted EBITDA outlook, and reaffirming its AMG visit guidance., Revenue in the range of $204 million to $206 million increased from $200 million to $205 million. AMG visits between 1.32 million and 1.37 million Adjusted EBITDA in the range between ($8) million to ($7) million increased from ($9) million to ($7) million.

The Company also provided financial guidance for Q4 2026 Revenue and adjusted EBITDA:

  • Q4 revenue in the range of $48 million to $50 million
  • Q4 adjusted EBITDA expected to in the range of $0 million to $1 million.

The Company also reiterated its objective to achieve positive cash flow from operations in the fourth quarter of 2026.

Serina Therapeutics (NYSE: SER)

Serina Theraeuptics (NYSE: SER, $1.42, +2.16%) is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.

On Thursday, November 12, Serina reported its financial results for the third quarter ended September 30, 2026, along with key business updates. Steve Ledger, Chief Executive Officer of Serina stated, “We are excited about the achievement of important clinical milestones for SER-252 in Parkinson’s disease, advancing from the initial evaluation of our lowest-dose cohort into the next stage of dose escalation. Importantly, the blinded pharmacokinetic observations from Cohort 1 showed the sustained drug exposure SER-252 was designed to achieve, and the independent Safety Monitoring Committee recommended proceeding with continued development. Dosing in Cohort 2 is currently underway and focuses on demonstrating SER-252’s potential as a differentiated treatment option for patients with advanced Parkinson’s disease to improve the significant challenge of consistent symptom control.”

On Thursday, September 24, 2026, Serina CEO Steve Ledger discussed discuss Serina’s programs’ progress during Tribe Public’s “A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress”webinar, followed by a live Q&A. You may view it below.

Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals Inc. (EPRX, $7.34), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today, ( Nov. 10), announced its financial results for the third quarter of 2026. Dr. James A. Helliwell, Chief Executive Officer of Eupraxia stated, “We remain on track to report interim results from the Phase 2b portion of the RESOLVE trial in December, and were pleased to announce in mid-October that we had reached our target enrollment of 120 patients. We are very encouraged by the Phase 1b/2a data from the open-label portion of the RESOLVE trial that was reported this quarter, which includes 36- and 52-week data from our highest dosing cohorts. We believe this data provides further evidence of the observed durable treatment effects of EP-104GI in EoE patients, seen in previous cohorts. In total, we have observed 64% of patients remaining in clinical remission over this 52-week period in addition to clinically meaningful histologic improvements. With cash runway into the second half of 2028, we believe we remain well funded to execute on our upcoming milestones for our EoE program.”

EPRX gained a significant new Wall Street endorsement Monday as RBC Capital Markets initiated coverage with an Outperform rating, a Speculative Risk designation and a $14 price target. The research makes a bullish case for EP-104GI, the company’s investigational treatment for eosinophilic esophagitis, ahead of an expected December clinical readout. Against the $6.89 reference price in RBC’s report, the target implies approximately 103% upside, not a forecast of where shares must trade. The attraction is unusually straightforward for biotechnology: take a familiar anti-inflammatory medicine, deliver it precisely into diseased tissue and attempt to make its benefits last long enough to change the treatment routine. If that approach succeeds, Eupraxia would offer more than another prescription for a chronic disease. It could offer a different calendar. RBC analyst Douglas Miehm’s November 9 initiation argues that EP-104GI could occupy a differentiated position in eosinophilic esophagitis, commonly called EoE, through localized delivery and the potential for once-yearly administration. The next major test is whether encouraging early results translate into convincing evidence against a vehicle control in the Phase 2b RESOLVE study.

EPRX announced (Oct. 15) that the ongoing RESOLVE study evaluating the safety and efficacy of EP-104GI for the treatment of Eosinophilic Esophagitis (“EoE”) has reached its enrollment target. “This is a significant milestone for the RESOLVE trial and the development of EP-104GI as a potential treatment option in EoE” said Dr. James Helliwell, Chief Executive Officer of Eupraxia. “We look forward to our interim analysis in December where we will be reporting on symptoms, histologic findings and safety in the first 60 patients in Phase 2b to reach 6 months. Data will also be available on the patients at 3, 9- and 12-month timepoints giving a fulsome interim look at the RESOLVE Trial”.

Modular Medical, Inc. (NASDAQ: MODD)

Modular Medical, Inc. (NASDAQ: MODD, $1.91, a commercial-stage medical device company preparing for the full commercial launch of its next-generation Pivot™ tubeless patch pump, is pursuing a different proposition: make insulin delivery less demanding for the people who must manage it every day. New patient research announced November 9 gives that strategy a persuasive commercial foundation. In a three-phase study conducted with Thrivable involving more than 540 people with Type 1 or Type 2 diabetes, approximately nine out of 10 surveyed multiple daily injection users said they would consider a simpler insulin delivery option. In the final-phase survey of 303 participants, 48.5% expressed strong interest in the company’s Pivot tubeless patch pump. The distinction matters. General enthusiasm for something easier is not the same as product-specific interest, and neither is a prescription. Still, the findings suggest Modular Medical is addressing a recognizable problem rather than inventing one for the benefit of a presentation deck. For many following MODD, the emerging opportunity centers on one word: simplicity. The company has already moved beyond the purely developmental stage. Its annual report documents U.S. Food and Drug Administration clearance for Pivot in April 2026, followed by commercial availability and initial patient shipments in June. The question now is whether a differentiated product, improving access and more focused patient education can turn that regulatory foundation into a repeatable commercial business.

MODD announced (Oct. 27) that it has received a positive decision from its notified body regarding certification of its quality management system under ISO 13485:2016. The notified body is designated under the European Union Medical Device Regulation (“MDR”).

MODD CEO, Jeb Besser, co-hosted a Tribe Public’s CEO Presentation and Q&A Webinar Event titled “The Road To Revenue: Modular Medical’s Strategy For Launching Pivot,” that was held Friday, September 4, 2026.. You may watch the event video below now if you missed it below now.

Alphabet (NASDAQ: GOOGL $283.72, -4.07%)

Alphabet (NASDAQ: GOOGL, GOOG) is confronting an expensive paradox: Artificial intelligence is bringing more activity to Google while making the economics of that activity harder to predict. Yet the latest results offer a more constructive interpretation than a simple obituary for search. Third-quarter revenue increased 25% to $127.6 billion. Operating income climbed 30% to $40.6 billion. Google Cloud revenue more than doubled. Those are unusual credentials for a company supposedly being escorted toward technological irrelevance. At the close on Thursday, Alphabet shares traded at $283.82, following a 12.64% decline, many are clearly demanding more proof and fewer architectural renderings of future data centers. That skepticism is understandable. But the opportunity lies in distinguishing a difficult transition in monetization from a collapse in demand. Google’s problem is not that people have stopped asking questions. According to management, its year-over-year search-query growth reached its highest rate in five years during the third quarter. The more consequential question is how quickly Google can turn its expanding AI audience into attractive, durable cash flow. Wall Street has little patience for a renovation when the contractor’s estimate begins with a trillion.

Space Exploration Technologies Corp. (SPCX, $137.36, -1.26%)

SpaceX-related coverage is orbiting three themes: a possible combination with Tesla, an expanding AI infrastructure footprint, and robust Starlink demand, because apparently conquering one industry at a time is inefficient. Reported third-quarter revenue totaled $14.6 billion, while management projected first-quarter 2027 revenue of $33 billion–$37 billion, a range with little apparent interest in remaining earthbound. The latest reporte

The Sources

  1. November 16 market live coverage: AI earnings, public-offering expectations and the economic calendar.
  2. Market preview: Nvidia earnings and an anticipated AI public offering.
  3. Nvidia board and Jensen Huang leadership update.
  4. Crude oil declines as Middle East exports recover.
  5. California’s lawsuit against OpenAI.
  6. Robert Pattinson announced as the next James Bond.
  7. Warren Buffett’s approximately $5.5 billion charitable donation.
  8. Prediction-market pricing for a possible Tesla and SpaceX merger.
  9. Eli Lilly’s agreement to acquire Calytrix Bio.
  10. SpaceX’s Starship recovery and the potential Tesla combination.
  11. Federal Reserve Bank of New York: November 2026 Empire State Manufacturing Survey.
  12. Federal Reserve Bank of New York: Empire State Manufacturing Survey methodology and overview.
  13. Technology outages disrupt email, air travel, enterprise software and online banking.

Disclosure: This article is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any security. Market data are subject to revision, and investors should conduct independent due diligence before making investment decisions. Investments may involve substantial risk, including the potential loss of the entire investment. Investors should conduct independent due diligence and consider their individual objectives and risk tolerance. See The Complete Disclosure via this link & at the top of the page.